2.
吉非替尼组和厄洛替尼组疗效
Tumor response in gefitinib-treated and erlotinib-treated patients
| Response | Gefitinib group (n=30) | Erlotinib group (n=31) | P |
| CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; DCR: disease control rate; RR: response rate. | |||
| CR | 0 | 0 | |
| PR | 3 | 7 | |
| SD | 15 | 16 | |
| PD | 12 | 8 | |
| DCR | 60.00% | 74.19% | 0.237, 8 |
| RR | 10.00% | 22.58% | 0.300, 6 |